I am a healthcare professional

Notice


Welcome to MEDICALLY. This website is a non-promotional international resource intended to facilitate transparent scientific exchange regarding developments in medical research and disease management. It is intended for healthcare professionals outside the United Kingdom (UK) and Australia. The content on this website may include scientific information about experimental or investigational compounds, indications and services that are not approved or valid in your jurisdiction. Registration status and prescribing information of medicinal products may differ between countries. Roche and Genentech do not support, endorse or recommend the unapproved use of any compound or service in your jurisdiction, including those discussed on this website.


Please refer to local product information for any medicinal products mentioned. Information available on this website does not constitute professional medical advice, and Roche and Genentech accept no responsibility for access to or use of the same. Healthcare professionals outside the US are required to register and log-in to access the full range of content available on this website.


By clicking on one of the healthcare professional buttons below, you acknowledge you have read and understood this message and that you are requesting access to MEDICALLY. If you are not a healthcare professional, please use the other links below to access information relevant to you.


Cookies


We use cookies on this site to enable the site to function properly and to enhance your user experience. Cookies are files stored in your browser, which most websites use to personalize your web experience. Your information will only be used to provide information that is relevant to you. It will not be used for any other purpose. If you wish to restrict or block cookies, which are set on your device, then you can do this through your browser settings.


You can find out more about cookies by browsing our Privacy Policy.

 

I am a healthcare professional in Canada

Required field.

For healthcare professionals in Another Country browse medically.roche.com.

Not a healthcare professional? For individuals outside the US, browse Roche's patient website or roche.com. For individuals in the US, browse gene.com.

External site

By following this link, you are leaving Medically and entering a website that is not owned or controlled by Roche. Roche does not take any responsibility for access to or use of this website, nor for any content therein.

Leave site
Home Oncology EASL ILC 2023
Roche and Genentech at

EASL ILC 2023

June 21 - June 24
Vienna, Austria
easlcongress.eu
Add to calendar
Share feedback
Share page
-
Medical Materials
Agenda
Coming soon

Sign up or login to unlock the full suite of MEDICALLY features
Jun 24 / Roche
Performance of the cobas HBV RNA assay for use on the cobas 5800/6800/8800 Systems (RUO) against genomic variants and transcript heterogeneity
Circulating hepatitis B virus RNA (HBV cirB-RNA) reflects the presence and transcriptional activity of covalently closed circular DNA (cccDNA) and is, therefore, being explored for use as a PCR diagnostic target for monitoring viral clearance and informing treatment decisions. The cobas® HBV RNA assay for use on the cobas 5800/6800/8800 systems (Research-Use Only) targets the 3′ end of cirB-RNA transcribed from HBV cccDNA, allowing differentiation from pregenomic RNA. This study assessed the impact of HBV genomic polymorphisms and transcript diversity on the performance of the assay. The genomic variations and poly-A tail heterogeneity detected in the study had a minimal impact on assay performance. The assay design was improved with additional primers to match rare genomic mismatches.
Infectious Disease Hepatitis B EASL-ILC-2023

Sign up or login to unlock the full suite of MEDICALLY features
Jun 24 / Roche
Development, Clinical Validation and Implementation of a Novel Algorithmic Score (GAAD) for the Detection of Early-stage Hepatocellular Carcinoma
This study aims to establish and train the algorithm coefficients, and clinically validate the performance of the GAAD algorithm in differentiating HCC and benign chronic liver disease (CLD), across different regions and aetiologies.
Oncology HealthTech Hepatocellular Carcinoma EASL-ILC-2023

Sign up or login to unlock the full suite of MEDICALLY features
Jun 24 / Roche
A New Biomarker Panel for Differential Diagnosis of Cholangiocarcinoma: Results from an Exploratory Analysis
This study aims to identify individual and combinations of serum tumor biomarkers that could distinguish CCA samples from those with HCC and benign chronic liver disease (CLD) controls using an approach established in a previously published study.
Oncology Cholangiocarcinoma EASL-ILC-2023
10:30 AM
Duration 12mins Vienna, Austria
Efficacy, safety and patient-reported outcomes (PROs) from the Phase III IMbrave050 trial of adjuvant atezolizumab (atezo) + bevacizumab (bev) vs active surveillance in patients with hepatocellular carcinoma (HCC) at high risk of disease recurrence following resection or ablation
Ahmed Kaseb, Minshan Chen, Pierce Chow, Masatoshi Kudo, Han Chu Lee, Adam Yopp, Lars Becker, Sairy Hernandez, Bruno Kovic, Qinshu Lian, Ning Ma, Chun Wu, Shukui Qin, Ann-Lii Cheng
Oncology | Gastrointestinal Cancer - Hepatocellular Carcinoma

You have successfully signed up for this alert. You will be notified when it is available.

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar

This website is intended for healthcare professionals outside the United Kingdom (UK) and Australia. Registration status and prescribing information of medicinal products may differ between countries. Please refer to local product information for any medicinal products mentioned on this website.